ArticleCureus2025
Intravitreal Dexamethasone Implant for Patients With Central Retinal Vein Occlusion: Four-Year Outcomes in a Real-World Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to present the long-term functional and anatomical outcomes of intravitreal dexamethasone (DEX) implant in patients with central retinal vein occlusion (CRVO) in real-world daily practice.
methodsRetrospective study of consecutive patients with macular edema due to CRVO, treated with 0.7 mg DEX implant and had 48-month follow-up. Data on best-corrected visual acuity (BCVA) and central subfield thickness (CST) at months 12, 24, 36, and 48 after initiation of DEX implant treatment were collected from patients' charts. Patient demographics and co-morbidities were also recorded, while potential factors affecting the final anatomical and functional outcomes were assessed.
resultsThirty-one patients (31 eyes) received a mean number of 4.1±1.1 DEX implants and demonstrated significantly improved BCVA at all time-points of follow-up (p<0.001 for all comparisons). Accordingly, CST decreased significantly at all time-points of follow-up (p<0.001 for all comparisons). Treatment naïve patients were found to have lower BCVA at month 48 compared to those who had previously received intravitreal aflibercept, although there was no difference regarding CST between the two groups at month 48. When assessing factors that may predict the outcome, only naïve administration of treatment was found to have a negative correlation with BCVA at 48 months.
conclusionsIn this series of patients with macular edema secondary to CRVO, a demonstrable improvement in BCVA was recorded along with CST decrease at a long-term follow-up of four years. Only naïve treatment with DEX implant negatively correlated with visual acuity outcomes, but it was not confirmed at the multivariate analysis. Therefore, there was no evidence to support a predictive relationship between demographic and baseline anatomical factors and final BCVA and CST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.